Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Acquired by Xponance Inc.

Xponance Inc. boosted its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 4.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 17,400 shares of the biotechnology company’s stock after acquiring an additional 744 shares during the period. Xponance Inc.’s holdings in Arrowhead Pharmaceuticals were worth $327,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in ARWR. HighTower Advisors LLC lifted its holdings in shares of Arrowhead Pharmaceuticals by 11.5% in the third quarter. HighTower Advisors LLC now owns 123,477 shares of the biotechnology company’s stock valued at $2,401,000 after purchasing an additional 12,706 shares in the last quarter. Intech Investment Management LLC acquired a new position in shares of Arrowhead Pharmaceuticals during the 3rd quarter worth approximately $659,000. Erste Asset Management GmbH purchased a new stake in Arrowhead Pharmaceuticals in the 3rd quarter valued at approximately $924,000. Geode Capital Management LLC lifted its stake in Arrowhead Pharmaceuticals by 0.9% in the 3rd quarter. Geode Capital Management LLC now owns 2,964,119 shares of the biotechnology company’s stock valued at $57,426,000 after buying an additional 26,171 shares in the last quarter. Finally, State Street Corp grew its holdings in Arrowhead Pharmaceuticals by 8.8% during the 3rd quarter. State Street Corp now owns 6,354,331 shares of the biotechnology company’s stock valued at $123,083,000 after buying an additional 516,569 shares during the last quarter. 62.61% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have recently issued reports on ARWR shares. HC Wainwright restated a “buy” rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, February 12th. Royal Bank of Canada restated an “outperform” rating and issued a $42.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. Chardan Capital reaffirmed a “buy” rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. StockNews.com raised shares of Arrowhead Pharmaceuticals to a “sell” rating in a research report on Friday, December 20th. Finally, B. Riley restated a “buy” rating and set a $38.00 target price (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, February 14th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $41.44.

Arrowhead Pharmaceuticals Stock Performance

Shares of ARWR stock opened at $13.80 on Friday. The company has a debt-to-equity ratio of 7.27, a quick ratio of 6.09 and a current ratio of 6.09. The firm has a market capitalization of $1.89 billion, a price-to-earnings ratio of -2.67 and a beta of 0.92. Arrowhead Pharmaceuticals, Inc. has a one year low of $13.68 and a one year high of $30.41. The company has a 50 day moving average price of $18.24 and a 200 day moving average price of $19.68.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.97). Sell-side analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Christopher Richard Anzalone sold 11,520 shares of the stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $19.05, for a total value of $219,456.00. Following the completion of the sale, the chief executive officer now owns 3,764,252 shares of the company’s stock, valued at $71,709,000.60. This represents a 0.31 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Patrick O’brien sold 29,184 shares of Arrowhead Pharmaceuticals stock in a transaction on Monday, January 6th. The shares were sold at an average price of $19.82, for a total transaction of $578,426.88. Following the transaction, the chief operating officer now owns 535,201 shares in the company, valued at $10,607,683.82. The trade was a 5.17 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 286,317 shares of company stock worth $5,049,735 over the last three months. 4.30% of the stock is owned by insiders.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.